UCB estimates upped by Merrill Lynch

UCB was reiterated by Merrill Lynch analyst Erica Whittaker at a buy rating but raised the EPS estimate for 2005 to €2.05 from €1.94, as well as estimates through 2010. On Wednesday, Merrill upped its price target on the stock to €48.00 per share from €42.00 following positive top line results for its drug Cimzia in Crohn's disease. UCB shares Thursday were up €0.80, or 1.81%, at €45.10 on volume of 779,779 shares versus the three-month running average of 262,109 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.